Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) EBIT: ฿156.7 Mil (TTM As of Mar. 2026)


BKK:AMARC Asia Medical and Agricultural Laboratory and Research Center PCL BKK:AMARC
79 GF Score
Price ฿3.56
GF Value ฿2.55
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Asia Medical and Agricultural Laboratory and Research Center PCL EBIT?

Asia Medical and Agricultural Laboratory and Research Center PCL BKK:AMARC -1.11% 79 EBIT is ฿156.7 Mil as of Mar. 2026. GuruFocus rates BKK:AMARC with a GF Score™ of 79/100 and a GF Value™ of ฿2.55 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Asia Medical and Agricultural Laboratory and Research Center PCL's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ฿21.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ฿156.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Asia Medical and Agricultural Laboratory and Research Center PCL's annualized ROC % for the quarter that ended in Mar. 2026 was 17.70%. Asia Medical and Agricultural Laboratory and Research Center PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 21.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Asia Medical and Agricultural Laboratory and Research Center PCL's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 12.10%.

Asia Medical and Agricultural Laboratory and Research Center PCL  (BKK:AMARC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Asia Medical and Agricultural Laboratory and Research Center PCL's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=86.92 * ( 1 - 0% )/( (481.925 + 500.21)/ 2 )
=86.92/491.0675
=17.70 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=705.383 - 37.896 - ( 185.562 - max(0, 54.814 - 262.083+185.562))
=481.925

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=703.842 - 33.443 - ( 170.189 - max(0, 48.983 - 249.364+170.189))
=500.21

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Asia Medical and Agricultural Laboratory and Research Center PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=86.92/( ( (387.354 + max(22.937, 0)) + (387.958 + max(22.573, 0)) )/ 2 )
=86.92/( ( 410.291 + 410.531 )/ 2 )
=86.92/410.411
=21.18 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(49.711 + 12.798 + 3.465) - (37.896 + 1.869 + 3.272)
=22.937

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(43.577 + 13.397 + 3.816) - (33.443 + 1.876 + 2.898)
=22.573

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Asia Medical and Agricultural Laboratory and Research Center PCL's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=156.675/1294.780
=12.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Asia Medical and Agricultural Laboratory and Research Center PCL EBIT Related Terms

Asia Medical and Agricultural Laboratory and Research Center PCL EBIT Historical Data

* Premium members only.

The historical data trend for Asia Medical and Agricultural Laboratory and Research Center PCL's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Asia Medical and Agricultural Laboratory and Research Center PCL EBIT Chart

Asia Medical and Agricultural Laboratory and Research Center PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 34.37 24.12 15.45 41.38 158.27

Asia Medical and Agricultural Laboratory and Research Center PCL Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.32 77.40 41.95 15.60 21.73

BKK:AMARC vs COHR, KEYS, GRMN: EBIT Comparison

For the Scientific & Technical Instruments subindustry, Asia Medical and Agricultural Laboratory and Research Center PCL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Asia Medical and Agricultural Laboratory and Research Center PCL EV-to-EBIT vs Hardware Industry

For the Hardware industry and Technology sector, Asia Medical and Agricultural Laboratory and Research Center PCL's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Asia Medical and Agricultural Laboratory and Research Center PCL's EV-to-EBIT falls into.


BKK:AMARC
79GF Score
Asia Medical and Agricultural Laboratory and Research Center PCL BKK:AMARC
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Asia Medical and Agricultural Laboratory and Research Center PCL EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿156.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ฿156.7 Mil mean?
Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) has a EBIT of ฿156.7 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Asia Medical and Agricultural Laboratory and Research Center PCL.
Is Asia Medical and Agricultural Laboratory and Research Center PCL's EBIT too high?
Asia Medical and Agricultural Laboratory and Research Center PCL's current EBIT is ฿156.7 Mil. Overall, Asia Medical and Agricultural Laboratory and Research Center PCL has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asia Medical and Agricultural Laboratory and Research Center PCL's EBIT compare to COHR and KEYS?
Asia Medical and Agricultural Laboratory and Research Center PCL's EBIT of ฿156.7 Mil can be compared against companies in the Hardware industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Hardware company?
A good EBIT depends on the Hardware industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Asia Medical and Agricultural Laboratory and Research Center PCL. Asia Medical and Agricultural Laboratory and Research Center PCL's current EBIT is ฿156.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asia Medical and Agricultural Laboratory and Research Center PCL stock overvalued right now?
Based on GuruFocus' analysis, Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) is currently considered Significantly Overvalued. The stock's GF Value™ is ฿2.55, compared to a current price of ฿3.56 — trading 39.6% above its estimated fair value. The current EBIT is ฿156.7 Mil. Asia Medical and Agricultural Laboratory and Research Center PCL's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC), the current EBIT is ฿156.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) Overvalued in 2026?

Based on GuruFocus' analysis, Asia Medical and Agricultural Laboratory and Research Center PCL stock appears to be overvalued. The current stock price of ฿3.56 is trading 39.6% above its estimated GF Value™ of ฿2.55. GuruFocus considers Asia Medical and Agricultural Laboratory and Research Center PCL to be Significantly Overvalued.

Key valuation signals for BKK:AMARC:

  • EBIT: ฿156.7 Mil
  • GF Value™: ฿2.55 vs. price of ฿3.56 (39.6% above fair value)
  • GF Score™: 79/100 with 1 warning sign

No single metric tells the full story. See the BKK:AMARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Asia Medical and Agricultural Laboratory and Research Center PCL Business Description

Address 361 Soi Ladprao 122, Ladprao Road, Phlabphla, Wang Thonglang, Bangkok, THA, 10310
Asia Medical and Agricultural Laboratory and Research Center PCL is engaged in providing comprehensive scientific services for the agriculture, food, pharmaceutical and environment sectors including testing, calibration, inspection and certification according to international quality standards. The company geographically operates only in Thailand.
79GF Score

Get the complete analysis for BKK:AMARC

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿3.56
Price
฿2.55
GF Value